# Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma

> **NCT02452554** · PHASE2 · COMPLETED · sponsor: **Children's Oncology Group** · enrollment: 62 (actual)

## Conditions studied

- Pleuropulmonary Blastoma
- Recurrent Malignant Peripheral Nerve Sheath Tumor
- Recurrent Neuroblastoma
- Recurrent Rhabdomyosarcoma
- Recurrent Synovial Sarcoma
- Wilms Tumor

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **BIOLOGICAL:** Lorvotuzumab Mertansine
- **OTHER:** Pharmacological Study

## Key facts

- **NCT ID:** NCT02452554
- **Lead sponsor:** Children's Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10-12
- **Primary completion:** 2017-06-30
- **Final completion:** 2021-09-30
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2022-01-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02452554

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02452554, "Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02452554. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*